Compare FLOC & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLOC | HELP |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 806.0M | 712.2M |
| IPO Year | 2024 | 2020 |
| Metric | FLOC | HELP |
|---|---|---|
| Price | $22.97 | $11.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $28.50 | ★ $51.50 |
| AVG Volume (30 Days) | 505.5K | ★ 1.9M |
| Earning Date | 05-06-2026 | 07-01-2026 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $759,719,000.00 | N/A |
| Revenue This Year | $22.92 | N/A |
| Revenue Next Year | $8.59 | N/A |
| P/E Ratio | $45.02 | ★ N/A |
| Revenue Growth | ★ 41.93 | N/A |
| 52 Week Low | $14.03 | $3.76 |
| 52 Week High | $28.26 | $12.05 |
| Indicator | FLOC | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 59.55 | 68.30 |
| Support Level | $22.54 | $4.41 |
| Resistance Level | $24.37 | N/A |
| Average True Range (ATR) | 0.99 | 0.80 |
| MACD | 0.34 | 0.13 |
| Stochastic Oscillator | 76.29 | 87.44 |
Flowco Holdings Inc is a provider of production optimization, artificial lift, emissions management, and monetization solutions for the oil and natural gas industry. Its technologies include high-pressure gas lift (HPGL), conventional gas lift, plunger lift, and vapor recovery unit (VRU) solutions. The company operates in two reportable segments: Production Solutions, which includes rental services, and Natural Gas Technologies, which include service, gas compression parts, and equipment sales. Production Solutions: relates to rentals, sales, and services related to high-pressure gas lift, conventional gas lift, and plunger lift; including other digital solutions and methane abatement technologies, and has maximum revenue. It generates maximum revenue from the United States.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.